Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
OBJECTIVE
To test the activity of tigecycline against bacterial isolates including multi-drug resistant (MDR) gram negative and gram positive organisms from intensive care patients.


METHODS
Clinically significant gram positive and MDR gram negative isolates from specimens of patients in the intensive care units of King Khalid University Hospital (KKUH), Riyadh, Kingdom of Saudi Arbia between November 1, 2006 and December 31, 2008 were tested against tigecycline by disc diffusion (DD) method. In some isolates, the minimal inhibitory concentration was carried out by E-test method. Some of the gram negative isolates, and gram positive isolates were tested using both methods. The study was approved by the hospital ethics committee.


RESULTS
All the 83 gram positive organisms tested by both DD and E-test were susceptible to tigecycline. Two hundred and fifty-four MDR gram negative isolates were tested for susceptibility to tigecycline. Of these 176 tested by DD, 159 (90%) were susceptible, 6 (3.4%) were resistant, and 11 (6.2%) were intermediately susceptible (data are not the same in table 3). From the 188 isolates tested by E-test, 140 (74.4%) were susceptible, 35 (18.6%) were resistant, and 13 (6.9%) showed intermediate susceptibility. For comparison between the methods, 109 isolates of the MDR gram negative organisms were tested by both E test and DD. The difference between the 2 methods was not significant.


CONCLUSIONS
Tigecycline was active against gram positive and most MDR gram negative isolates from patients in medical and surgical intensive cases in KKUH. There was no significant difference between the DD and E-test methods for susceptibility testing of tigecycline against these isolates.
Somily
Ali M
AM
Department of Pathology/Microbiology, College of Medicine & King Saud University, King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia. ali.somily@gmail.com
Al-Khattaf
Abdulaziz S
AS
Kambal
Abdelmageed M
AM
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D052978:Disk Diffusion Antimicrobial Tests; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006784:Hospitals, Teaching; D006801:Humans; D007362:Intensive Care Units; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012529:Saudi Arabia; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline